-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30

Benzinga·12/11/2025 14:31:08
語音播報
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.